nodes	percent_of_prediction	percent_of_DWPC	metapath
Irbesartan—JUN—kidney cancer	0.322	0.776	CbGaD
Irbesartan—JUN—Vinblastine—kidney cancer	0.181	0.514	CbGbCtD
Irbesartan—PTGS1—kidney cancer	0.0929	0.224	CbGaD
Irbesartan—CYP2D6—Temsirolimus—kidney cancer	0.0154	0.0438	CbGbCtD
Irbesartan—CYP3A4—Everolimus—kidney cancer	0.0145	0.0412	CbGbCtD
Irbesartan—CYP2C8—Pazopanib—kidney cancer	0.0127	0.036	CbGbCtD
Irbesartan—CYP1A2—Pazopanib—kidney cancer	0.0098	0.0279	CbGbCtD
Irbesartan—CYP3A4—Temsirolimus—kidney cancer	0.00977	0.0278	CbGbCtD
Irbesartan—CYP2C9—Capecitabine—kidney cancer	0.00921	0.0262	CbGbCtD
Irbesartan—CYP2C8—Erlotinib—kidney cancer	0.00903	0.0257	CbGbCtD
Irbesartan—CYP2C8—Paclitaxel—kidney cancer	0.00827	0.0235	CbGbCtD
Irbesartan—CYP2D6—Pazopanib—kidney cancer	0.00807	0.023	CbGbCtD
Irbesartan—CYP2C8—Sorafenib—kidney cancer	0.00735	0.0209	CbGbCtD
Irbesartan—CYP1A2—Erlotinib—kidney cancer	0.00699	0.0199	CbGbCtD
Irbesartan—CYP2C9—Paclitaxel—kidney cancer	0.00577	0.0164	CbGbCtD
Irbesartan—CYP2D6—Erlotinib—kidney cancer	0.00576	0.0164	CbGbCtD
Irbesartan—CYP1A2—Sorafenib—kidney cancer	0.00569	0.0162	CbGbCtD
Irbesartan—JUN—nephron—kidney cancer	0.0055	0.176	CbGeAlD
Irbesartan—CYP3A4—Pazopanib—kidney cancer	0.00513	0.0146	CbGbCtD
Irbesartan—CYP2C9—Sorafenib—kidney cancer	0.00512	0.0146	CbGbCtD
Irbesartan—CYP2D6—Sorafenib—kidney cancer	0.00468	0.0133	CbGbCtD
Irbesartan—CYP2D6—Vinblastine—kidney cancer	0.00463	0.0132	CbGbCtD
Irbesartan—AGTR1—nephron—kidney cancer	0.00414	0.133	CbGeAlD
Irbesartan—CYP3A4—Erlotinib—kidney cancer	0.00366	0.0104	CbGbCtD
Irbesartan—CYP3A4—Paclitaxel—kidney cancer	0.00335	0.00955	CbGbCtD
Irbesartan—CYP3A4—Sorafenib—kidney cancer	0.00298	0.00848	CbGbCtD
Irbesartan—CYP3A4—Vinblastine—kidney cancer	0.00294	0.00837	CbGbCtD
Irbesartan—CYP3A4—Vincristine—kidney cancer	0.00289	0.00823	CbGbCtD
Irbesartan—CYP2D6—Doxorubicin—kidney cancer	0.00284	0.00809	CbGbCtD
Irbesartan—CYP3A4—Sunitinib—kidney cancer	0.00241	0.00687	CbGbCtD
Irbesartan—CYP3A4—Doxorubicin—kidney cancer	0.00181	0.00514	CbGbCtD
Irbesartan—CYP1A2—urine—kidney cancer	0.00169	0.054	CbGeAlD
Irbesartan—CYP2C9—urine—kidney cancer	0.0016	0.0512	CbGeAlD
Irbesartan—CYP3A4—urine—kidney cancer	0.00122	0.0391	CbGeAlD
Irbesartan—CYP2D6—urine—kidney cancer	0.0012	0.0384	CbGeAlD
Irbesartan—JUN—nephron tubule—kidney cancer	0.00119	0.038	CbGeAlD
Irbesartan—EDNRA—cortex of kidney—kidney cancer	0.00111	0.0357	CbGeAlD
Irbesartan—JUN—renal system—kidney cancer	0.00108	0.0346	CbGeAlD
Irbesartan—EDNRA—cardiac atrium—kidney cancer	0.00106	0.0339	CbGeAlD
Irbesartan—JUN—kidney—kidney cancer	0.00104	0.0334	CbGeAlD
Irbesartan—JUN—cortex of kidney—kidney cancer	0.00102	0.0325	CbGeAlD
Irbesartan—JUN—gonad—kidney cancer	0.000969	0.031	CbGeAlD
Irbesartan—JUN—cardiac atrium—kidney cancer	0.000967	0.031	CbGeAlD
Irbesartan—AGTR1—nephron tubule—kidney cancer	0.000895	0.0286	CbGeAlD
Irbesartan—AGTR1—renal system—kidney cancer	0.000813	0.026	CbGeAlD
Irbesartan—AGTR1—kidney—kidney cancer	0.000786	0.0252	CbGeAlD
Irbesartan—AGTR1—cortex of kidney—kidney cancer	0.000766	0.0245	CbGeAlD
Irbesartan—AGTR1—cardiac atrium—kidney cancer	0.000728	0.0233	CbGeAlD
Irbesartan—CYP2C8—renal system—kidney cancer	0.000441	0.0141	CbGeAlD
Irbesartan—CYP2C8—kidney—kidney cancer	0.000426	0.0136	CbGeAlD
Irbesartan—CYP1A2—renal system—kidney cancer	0.000413	0.0132	CbGeAlD
Irbesartan—PTGS1—renal system—kidney cancer	0.000358	0.0114	CbGeAlD
Irbesartan—PTGS1—kidney—kidney cancer	0.000346	0.0111	CbGeAlD
Irbesartan—PTGS1—cardiac atrium—kidney cancer	0.00032	0.0102	CbGeAlD
Irbesartan—CYP3A4—renal system—kidney cancer	0.000299	0.00956	CbGeAlD
Irbesartan—CYP2D6—renal system—kidney cancer	0.000294	0.0094	CbGeAlD
Irbesartan—CYP3A4—kidney—kidney cancer	0.000289	0.00924	CbGeAlD
Irbesartan—Candesartan—PTGS1—kidney cancer	0.000287	0.556	CrCbGaD
Irbesartan—CYP2D6—kidney—kidney cancer	0.000284	0.00909	CbGeAlD
Irbesartan—Candesartan—ABCB1—kidney cancer	0.00014	0.27	CrCbGaD
Irbesartan—Losartan—ABCB1—kidney cancer	8.99e-05	0.174	CrCbGaD
Irbesartan—Chills—Capecitabine—kidney cancer	5e-05	0.000407	CcSEcCtD
Irbesartan—Unspecified disorder of skin and subcutaneous tissue—Paclitaxel—kidney cancer	5e-05	0.000406	CcSEcCtD
Irbesartan—Arrhythmia—Capecitabine—kidney cancer	4.98e-05	0.000405	CcSEcCtD
Irbesartan—Gastrointestinal disorder—Gemcitabine—kidney cancer	4.97e-05	0.000405	CcSEcCtD
Irbesartan—Discomfort—Paclitaxel—kidney cancer	4.97e-05	0.000404	CcSEcCtD
Irbesartan—Fatigue—Gemcitabine—kidney cancer	4.97e-05	0.000404	CcSEcCtD
Irbesartan—Gastrointestinal pain—Vincristine—kidney cancer	4.97e-05	0.000404	CcSEcCtD
Irbesartan—Dizziness—Sorafenib—kidney cancer	4.93e-05	0.000401	CcSEcCtD
Irbesartan—Constipation—Gemcitabine—kidney cancer	4.93e-05	0.000401	CcSEcCtD
Irbesartan—Pain—Gemcitabine—kidney cancer	4.93e-05	0.000401	CcSEcCtD
Irbesartan—Nausea—Erlotinib—kidney cancer	4.93e-05	0.000401	CcSEcCtD
Irbesartan—Dry mouth—Paclitaxel—kidney cancer	4.92e-05	0.0004	CcSEcCtD
Irbesartan—Mood swings—Doxorubicin—kidney cancer	4.92e-05	0.0004	CcSEcCtD
Irbesartan—Diarrhoea—Sunitinib—kidney cancer	4.91e-05	0.0004	CcSEcCtD
Irbesartan—Asthenia—Dactinomycin—kidney cancer	4.88e-05	0.000397	CcSEcCtD
Irbesartan—Malnutrition—Capecitabine—kidney cancer	4.85e-05	0.000394	CcSEcCtD
Irbesartan—Erythema—Capecitabine—kidney cancer	4.85e-05	0.000394	CcSEcCtD
Irbesartan—Oedema—Paclitaxel—kidney cancer	4.82e-05	0.000392	CcSEcCtD
Irbesartan—Anaphylactic shock—Paclitaxel—kidney cancer	4.82e-05	0.000392	CcSEcCtD
Irbesartan—Abdominal pain—Vincristine—kidney cancer	4.8e-05	0.00039	CcSEcCtD
Irbesartan—Body temperature increased—Vincristine—kidney cancer	4.8e-05	0.00039	CcSEcCtD
Irbesartan—Liver function test abnormal—Doxorubicin—kidney cancer	4.79e-05	0.00039	CcSEcCtD
Irbesartan—Infection—Paclitaxel—kidney cancer	4.79e-05	0.00039	CcSEcCtD
Irbesartan—Flatulence—Capecitabine—kidney cancer	4.78e-05	0.000389	CcSEcCtD
Irbesartan—Dysgeusia—Capecitabine—kidney cancer	4.75e-05	0.000386	CcSEcCtD
Irbesartan—Dizziness—Sunitinib—kidney cancer	4.75e-05	0.000386	CcSEcCtD
Irbesartan—Feeling abnormal—Gemcitabine—kidney cancer	4.75e-05	0.000386	CcSEcCtD
Irbesartan—Shock—Paclitaxel—kidney cancer	4.75e-05	0.000386	CcSEcCtD
Irbesartan—Vomiting—Sorafenib—kidney cancer	4.74e-05	0.000386	CcSEcCtD
Irbesartan—Orthostatic hypotension—Doxorubicin—kidney cancer	4.74e-05	0.000386	CcSEcCtD
Irbesartan—Abdominal pain upper—Doxorubicin—kidney cancer	4.74e-05	0.000386	CcSEcCtD
Irbesartan—Nervous system disorder—Paclitaxel—kidney cancer	4.73e-05	0.000385	CcSEcCtD
Irbesartan—Hypokalaemia—Doxorubicin—kidney cancer	4.72e-05	0.000384	CcSEcCtD
Irbesartan—Thrombocytopenia—Paclitaxel—kidney cancer	4.72e-05	0.000384	CcSEcCtD
Irbesartan—Tachycardia—Paclitaxel—kidney cancer	4.71e-05	0.000383	CcSEcCtD
Irbesartan—Rash—Sorafenib—kidney cancer	4.7e-05	0.000383	CcSEcCtD
Irbesartan—Dermatitis—Sorafenib—kidney cancer	4.7e-05	0.000382	CcSEcCtD
Irbesartan—Breast disorder—Doxorubicin—kidney cancer	4.69e-05	0.000382	CcSEcCtD
Irbesartan—Skin disorder—Paclitaxel—kidney cancer	4.68e-05	0.000381	CcSEcCtD
Irbesartan—Toxic epidermal necrolysis—Doxorubicin—kidney cancer	4.67e-05	0.00038	CcSEcCtD
Irbesartan—Headache—Sorafenib—kidney cancer	4.67e-05	0.00038	CcSEcCtD
Irbesartan—Muscle spasms—Capecitabine—kidney cancer	4.66e-05	0.000379	CcSEcCtD
Irbesartan—Hyperhidrosis—Paclitaxel—kidney cancer	4.66e-05	0.000379	CcSEcCtD
Irbesartan—Diarrhoea—Dactinomycin—kidney cancer	4.65e-05	0.000378	CcSEcCtD
Irbesartan—Nasopharyngitis—Doxorubicin—kidney cancer	4.64e-05	0.000378	CcSEcCtD
Irbesartan—Anorexia—Paclitaxel—kidney cancer	4.6e-05	0.000374	CcSEcCtD
Irbesartan—Muscular weakness—Doxorubicin—kidney cancer	4.58e-05	0.000372	CcSEcCtD
Irbesartan—Vision blurred—Capecitabine—kidney cancer	4.57e-05	0.000372	CcSEcCtD
Irbesartan—Vomiting—Sunitinib—kidney cancer	4.56e-05	0.000371	CcSEcCtD
Irbesartan—Body temperature increased—Gemcitabine—kidney cancer	4.55e-05	0.00037	CcSEcCtD
Irbesartan—Tremor—Capecitabine—kidney cancer	4.54e-05	0.00037	CcSEcCtD
Irbesartan—Rash—Sunitinib—kidney cancer	4.53e-05	0.000368	CcSEcCtD
Irbesartan—Dermatitis—Sunitinib—kidney cancer	4.52e-05	0.000368	CcSEcCtD
Irbesartan—Abdominal distension—Doxorubicin—kidney cancer	4.52e-05	0.000367	CcSEcCtD
Irbesartan—Hypotension—Paclitaxel—kidney cancer	4.51e-05	0.000367	CcSEcCtD
Irbesartan—Ill-defined disorder—Capecitabine—kidney cancer	4.5e-05	0.000366	CcSEcCtD
Irbesartan—Headache—Sunitinib—kidney cancer	4.5e-05	0.000366	CcSEcCtD
Irbesartan—Influenza—Doxorubicin—kidney cancer	4.49e-05	0.000365	CcSEcCtD
Irbesartan—Asthma—Doxorubicin—kidney cancer	4.49e-05	0.000365	CcSEcCtD
Irbesartan—Dysphagia—Doxorubicin—kidney cancer	4.49e-05	0.000365	CcSEcCtD
Irbesartan—Anaemia—Capecitabine—kidney cancer	4.48e-05	0.000365	CcSEcCtD
Irbesartan—Hypersensitivity—Vincristine—kidney cancer	4.47e-05	0.000364	CcSEcCtD
Irbesartan—Nausea—Sorafenib—kidney cancer	4.43e-05	0.00036	CcSEcCtD
Irbesartan—Pancreatitis—Doxorubicin—kidney cancer	4.4e-05	0.000358	CcSEcCtD
Irbesartan—Musculoskeletal discomfort—Paclitaxel—kidney cancer	4.39e-05	0.000357	CcSEcCtD
Irbesartan—Malaise—Capecitabine—kidney cancer	4.37e-05	0.000356	CcSEcCtD
Irbesartan—Angina pectoris—Doxorubicin—kidney cancer	4.37e-05	0.000355	CcSEcCtD
Irbesartan—Vertigo—Capecitabine—kidney cancer	4.36e-05	0.000354	CcSEcCtD
Irbesartan—Asthenia—Vincristine—kidney cancer	4.36e-05	0.000354	CcSEcCtD
Irbesartan—Syncope—Capecitabine—kidney cancer	4.35e-05	0.000354	CcSEcCtD
Irbesartan—Leukopenia—Capecitabine—kidney cancer	4.34e-05	0.000353	CcSEcCtD
Irbesartan—Paraesthesia—Paclitaxel—kidney cancer	4.33e-05	0.000352	CcSEcCtD
Irbesartan—Vomiting—Dactinomycin—kidney cancer	4.32e-05	0.000352	CcSEcCtD
Irbesartan—Dyspnoea—Paclitaxel—kidney cancer	4.3e-05	0.00035	CcSEcCtD
Irbesartan—Somnolence—Paclitaxel—kidney cancer	4.29e-05	0.000349	CcSEcCtD
Irbesartan—Rash—Dactinomycin—kidney cancer	4.29e-05	0.000349	CcSEcCtD
Irbesartan—Nausea—Sunitinib—kidney cancer	4.26e-05	0.000347	CcSEcCtD
Irbesartan—Loss of consciousness—Capecitabine—kidney cancer	4.26e-05	0.000347	CcSEcCtD
Irbesartan—Dyspepsia—Paclitaxel—kidney cancer	4.25e-05	0.000345	CcSEcCtD
Irbesartan—Cough—Capecitabine—kidney cancer	4.23e-05	0.000344	CcSEcCtD
Irbesartan—Neutropenia—Doxorubicin—kidney cancer	4.2e-05	0.000341	CcSEcCtD
Irbesartan—Decreased appetite—Paclitaxel—kidney cancer	4.19e-05	0.000341	CcSEcCtD
Irbesartan—Hypertension—Capecitabine—kidney cancer	4.19e-05	0.000341	CcSEcCtD
Irbesartan—Upper respiratory tract infection—Doxorubicin—kidney cancer	4.17e-05	0.000339	CcSEcCtD
Irbesartan—Gastrointestinal disorder—Paclitaxel—kidney cancer	4.16e-05	0.000339	CcSEcCtD
Irbesartan—Fatigue—Paclitaxel—kidney cancer	4.16e-05	0.000338	CcSEcCtD
Irbesartan—Diarrhoea—Vincristine—kidney cancer	4.15e-05	0.000338	CcSEcCtD
Irbesartan—Asthenia—Gemcitabine—kidney cancer	4.13e-05	0.000336	CcSEcCtD
Irbesartan—Myalgia—Capecitabine—kidney cancer	4.13e-05	0.000336	CcSEcCtD
Irbesartan—Arthralgia—Capecitabine—kidney cancer	4.13e-05	0.000336	CcSEcCtD
Irbesartan—Chest pain—Capecitabine—kidney cancer	4.13e-05	0.000336	CcSEcCtD
Irbesartan—Pain—Paclitaxel—kidney cancer	4.12e-05	0.000335	CcSEcCtD
Irbesartan—Constipation—Paclitaxel—kidney cancer	4.12e-05	0.000335	CcSEcCtD
Irbesartan—Anxiety—Capecitabine—kidney cancer	4.11e-05	0.000335	CcSEcCtD
Irbesartan—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—kidney cancer	4.1e-05	0.000334	CcSEcCtD
Irbesartan—Photosensitivity reaction—Doxorubicin—kidney cancer	4.1e-05	0.000333	CcSEcCtD
Irbesartan—Weight increased—Doxorubicin—kidney cancer	4.08e-05	0.000332	CcSEcCtD
Irbesartan—Discomfort—Capecitabine—kidney cancer	4.08e-05	0.000332	CcSEcCtD
Irbesartan—Pruritus—Gemcitabine—kidney cancer	4.08e-05	0.000332	CcSEcCtD
Irbesartan—Hyperglycaemia—Doxorubicin—kidney cancer	4.05e-05	0.000329	CcSEcCtD
Irbesartan—Dry mouth—Capecitabine—kidney cancer	4.04e-05	0.000328	CcSEcCtD
Irbesartan—Nausea—Dactinomycin—kidney cancer	4.04e-05	0.000328	CcSEcCtD
Irbesartan—Pneumonia—Doxorubicin—kidney cancer	4.02e-05	0.000327	CcSEcCtD
Irbesartan—Dizziness—Vincristine—kidney cancer	4.02e-05	0.000327	CcSEcCtD
Irbesartan—Feeling abnormal—Paclitaxel—kidney cancer	3.97e-05	0.000323	CcSEcCtD
Irbesartan—Oedema—Capecitabine—kidney cancer	3.96e-05	0.000322	CcSEcCtD
Irbesartan—Gastrointestinal pain—Paclitaxel—kidney cancer	3.94e-05	0.000321	CcSEcCtD
Irbesartan—Diarrhoea—Gemcitabine—kidney cancer	3.94e-05	0.000321	CcSEcCtD
Irbesartan—Renal failure—Doxorubicin—kidney cancer	3.93e-05	0.00032	CcSEcCtD
Irbesartan—Infection—Capecitabine—kidney cancer	3.93e-05	0.00032	CcSEcCtD
Irbesartan—Jaundice—Doxorubicin—kidney cancer	3.9e-05	0.000317	CcSEcCtD
Irbesartan—Shock—Capecitabine—kidney cancer	3.89e-05	0.000317	CcSEcCtD
Irbesartan—Conjunctivitis—Doxorubicin—kidney cancer	3.89e-05	0.000316	CcSEcCtD
Irbesartan—Urinary tract infection—Doxorubicin—kidney cancer	3.89e-05	0.000316	CcSEcCtD
Irbesartan—Nervous system disorder—Capecitabine—kidney cancer	3.88e-05	0.000316	CcSEcCtD
Irbesartan—Thrombocytopenia—Capecitabine—kidney cancer	3.88e-05	0.000315	CcSEcCtD
Irbesartan—Tachycardia—Capecitabine—kidney cancer	3.86e-05	0.000314	CcSEcCtD
Irbesartan—Vomiting—Vincristine—kidney cancer	3.86e-05	0.000314	CcSEcCtD
Irbesartan—Skin disorder—Capecitabine—kidney cancer	3.84e-05	0.000313	CcSEcCtD
Irbesartan—Urticaria—Paclitaxel—kidney cancer	3.83e-05	0.000312	CcSEcCtD
Irbesartan—Rash—Vincristine—kidney cancer	3.83e-05	0.000311	CcSEcCtD
Irbesartan—Hyperhidrosis—Capecitabine—kidney cancer	3.83e-05	0.000311	CcSEcCtD
Irbesartan—Dermatitis—Vincristine—kidney cancer	3.83e-05	0.000311	CcSEcCtD
Irbesartan—Body temperature increased—Paclitaxel—kidney cancer	3.81e-05	0.00031	CcSEcCtD
Irbesartan—Abdominal pain—Paclitaxel—kidney cancer	3.81e-05	0.00031	CcSEcCtD
Irbesartan—Headache—Vincristine—kidney cancer	3.8e-05	0.000309	CcSEcCtD
Irbesartan—Hepatobiliary disease—Doxorubicin—kidney cancer	3.78e-05	0.000308	CcSEcCtD
Irbesartan—Epistaxis—Doxorubicin—kidney cancer	3.77e-05	0.000307	CcSEcCtD
Irbesartan—Anorexia—Capecitabine—kidney cancer	3.77e-05	0.000307	CcSEcCtD
Irbesartan—Agranulocytosis—Doxorubicin—kidney cancer	3.73e-05	0.000304	CcSEcCtD
Irbesartan—Hypotension—Capecitabine—kidney cancer	3.7e-05	0.000301	CcSEcCtD
Irbesartan—Vomiting—Gemcitabine—kidney cancer	3.66e-05	0.000298	CcSEcCtD
Irbesartan—Bradycardia—Doxorubicin—kidney cancer	3.66e-05	0.000297	CcSEcCtD
Irbesartan—Rash—Gemcitabine—kidney cancer	3.63e-05	0.000295	CcSEcCtD
Irbesartan—Dermatitis—Gemcitabine—kidney cancer	3.63e-05	0.000295	CcSEcCtD
Irbesartan—Headache—Gemcitabine—kidney cancer	3.61e-05	0.000294	CcSEcCtD
Irbesartan—Nausea—Vincristine—kidney cancer	3.61e-05	0.000293	CcSEcCtD
Irbesartan—Musculoskeletal discomfort—Capecitabine—kidney cancer	3.61e-05	0.000293	CcSEcCtD
Irbesartan—Rhinitis—Doxorubicin—kidney cancer	3.6e-05	0.000293	CcSEcCtD
Irbesartan—Hepatitis—Doxorubicin—kidney cancer	3.59e-05	0.000292	CcSEcCtD
Irbesartan—Hypoaesthesia—Doxorubicin—kidney cancer	3.57e-05	0.000291	CcSEcCtD
Irbesartan—Pharyngitis—Doxorubicin—kidney cancer	3.56e-05	0.00029	CcSEcCtD
Irbesartan—Paraesthesia—Capecitabine—kidney cancer	3.55e-05	0.000289	CcSEcCtD
Irbesartan—Hypersensitivity—Paclitaxel—kidney cancer	3.55e-05	0.000289	CcSEcCtD
Irbesartan—Urinary tract disorder—Doxorubicin—kidney cancer	3.55e-05	0.000288	CcSEcCtD
Irbesartan—Oedema peripheral—Doxorubicin—kidney cancer	3.54e-05	0.000288	CcSEcCtD
Irbesartan—Connective tissue disorder—Doxorubicin—kidney cancer	3.53e-05	0.000287	CcSEcCtD
Irbesartan—Dyspnoea—Capecitabine—kidney cancer	3.53e-05	0.000287	CcSEcCtD
Irbesartan—Urethral disorder—Doxorubicin—kidney cancer	3.52e-05	0.000286	CcSEcCtD
Irbesartan—Dyspepsia—Capecitabine—kidney cancer	3.48e-05	0.000283	CcSEcCtD
Irbesartan—Visual impairment—Doxorubicin—kidney cancer	3.46e-05	0.000282	CcSEcCtD
Irbesartan—Asthenia—Paclitaxel—kidney cancer	3.46e-05	0.000281	CcSEcCtD
Irbesartan—Decreased appetite—Capecitabine—kidney cancer	3.44e-05	0.00028	CcSEcCtD
Irbesartan—Nausea—Gemcitabine—kidney cancer	3.42e-05	0.000278	CcSEcCtD
Irbesartan—Gastrointestinal disorder—Capecitabine—kidney cancer	3.42e-05	0.000278	CcSEcCtD
Irbesartan—Fatigue—Capecitabine—kidney cancer	3.41e-05	0.000278	CcSEcCtD
Irbesartan—Pruritus—Paclitaxel—kidney cancer	3.41e-05	0.000278	CcSEcCtD
Irbesartan—Pain—Capecitabine—kidney cancer	3.38e-05	0.000275	CcSEcCtD
Irbesartan—Constipation—Capecitabine—kidney cancer	3.38e-05	0.000275	CcSEcCtD
Irbesartan—Tinnitus—Doxorubicin—kidney cancer	3.35e-05	0.000272	CcSEcCtD
Irbesartan—Flushing—Doxorubicin—kidney cancer	3.33e-05	0.000271	CcSEcCtD
Irbesartan—Cardiac disorder—Doxorubicin—kidney cancer	3.33e-05	0.000271	CcSEcCtD
Irbesartan—Diarrhoea—Paclitaxel—kidney cancer	3.3e-05	0.000268	CcSEcCtD
Irbesartan—Feeling abnormal—Capecitabine—kidney cancer	3.26e-05	0.000265	CcSEcCtD
Irbesartan—Angiopathy—Doxorubicin—kidney cancer	3.26e-05	0.000265	CcSEcCtD
Irbesartan—Immune system disorder—Doxorubicin—kidney cancer	3.24e-05	0.000264	CcSEcCtD
Irbesartan—Gastrointestinal pain—Capecitabine—kidney cancer	3.24e-05	0.000263	CcSEcCtD
Irbesartan—Mediastinal disorder—Doxorubicin—kidney cancer	3.24e-05	0.000263	CcSEcCtD
Irbesartan—Chills—Doxorubicin—kidney cancer	3.22e-05	0.000262	CcSEcCtD
Irbesartan—Arrhythmia—Doxorubicin—kidney cancer	3.21e-05	0.000261	CcSEcCtD
Irbesartan—Dizziness—Paclitaxel—kidney cancer	3.19e-05	0.000259	CcSEcCtD
Irbesartan—Urticaria—Capecitabine—kidney cancer	3.14e-05	0.000256	CcSEcCtD
Irbesartan—Body temperature increased—Capecitabine—kidney cancer	3.13e-05	0.000255	CcSEcCtD
Irbesartan—Abdominal pain—Capecitabine—kidney cancer	3.13e-05	0.000255	CcSEcCtD
Irbesartan—Erythema—Doxorubicin—kidney cancer	3.13e-05	0.000254	CcSEcCtD
Irbesartan—Malnutrition—Doxorubicin—kidney cancer	3.13e-05	0.000254	CcSEcCtD
Irbesartan—Flatulence—Doxorubicin—kidney cancer	3.08e-05	0.000251	CcSEcCtD
Irbesartan—Tension—Doxorubicin—kidney cancer	3.07e-05	0.00025	CcSEcCtD
Irbesartan—Vomiting—Paclitaxel—kidney cancer	3.07e-05	0.000249	CcSEcCtD
Irbesartan—Dysgeusia—Doxorubicin—kidney cancer	3.06e-05	0.000249	CcSEcCtD
Irbesartan—Rash—Paclitaxel—kidney cancer	3.04e-05	0.000247	CcSEcCtD
Irbesartan—Dermatitis—Paclitaxel—kidney cancer	3.04e-05	0.000247	CcSEcCtD
Irbesartan—Nervousness—Doxorubicin—kidney cancer	3.04e-05	0.000247	CcSEcCtD
Irbesartan—Headache—Paclitaxel—kidney cancer	3.02e-05	0.000246	CcSEcCtD
Irbesartan—Muscle spasms—Doxorubicin—kidney cancer	3.01e-05	0.000244	CcSEcCtD
Irbesartan—Vision blurred—Doxorubicin—kidney cancer	2.95e-05	0.00024	CcSEcCtD
Irbesartan—Hypersensitivity—Capecitabine—kidney cancer	2.92e-05	0.000237	CcSEcCtD
Irbesartan—Ill-defined disorder—Doxorubicin—kidney cancer	2.9e-05	0.000236	CcSEcCtD
Irbesartan—Anaemia—Doxorubicin—kidney cancer	2.89e-05	0.000235	CcSEcCtD
Irbesartan—Agitation—Doxorubicin—kidney cancer	2.87e-05	0.000234	CcSEcCtD
Irbesartan—Nausea—Paclitaxel—kidney cancer	2.86e-05	0.000233	CcSEcCtD
Irbesartan—Asthenia—Capecitabine—kidney cancer	2.84e-05	0.000231	CcSEcCtD
Irbesartan—Malaise—Doxorubicin—kidney cancer	2.82e-05	0.000229	CcSEcCtD
Irbesartan—Vertigo—Doxorubicin—kidney cancer	2.81e-05	0.000228	CcSEcCtD
Irbesartan—Syncope—Doxorubicin—kidney cancer	2.8e-05	0.000228	CcSEcCtD
Irbesartan—Pruritus—Capecitabine—kidney cancer	2.8e-05	0.000228	CcSEcCtD
Irbesartan—Leukopenia—Doxorubicin—kidney cancer	2.8e-05	0.000228	CcSEcCtD
Irbesartan—Loss of consciousness—Doxorubicin—kidney cancer	2.75e-05	0.000224	CcSEcCtD
Irbesartan—Cough—Doxorubicin—kidney cancer	2.73e-05	0.000222	CcSEcCtD
Irbesartan—Diarrhoea—Capecitabine—kidney cancer	2.71e-05	0.00022	CcSEcCtD
Irbesartan—Hypertension—Doxorubicin—kidney cancer	2.7e-05	0.00022	CcSEcCtD
Irbesartan—Myalgia—Doxorubicin—kidney cancer	2.66e-05	0.000216	CcSEcCtD
Irbesartan—Chest pain—Doxorubicin—kidney cancer	2.66e-05	0.000216	CcSEcCtD
Irbesartan—Arthralgia—Doxorubicin—kidney cancer	2.66e-05	0.000216	CcSEcCtD
Irbesartan—Anxiety—Doxorubicin—kidney cancer	2.65e-05	0.000216	CcSEcCtD
Irbesartan—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—kidney cancer	2.64e-05	0.000215	CcSEcCtD
Irbesartan—Discomfort—Doxorubicin—kidney cancer	2.63e-05	0.000214	CcSEcCtD
Irbesartan—Dizziness—Capecitabine—kidney cancer	2.62e-05	0.000213	CcSEcCtD
Irbesartan—Dry mouth—Doxorubicin—kidney cancer	2.6e-05	0.000212	CcSEcCtD
Irbesartan—Anaphylactic shock—Doxorubicin—kidney cancer	2.55e-05	0.000208	CcSEcCtD
Irbesartan—Oedema—Doxorubicin—kidney cancer	2.55e-05	0.000208	CcSEcCtD
Irbesartan—Infection—Doxorubicin—kidney cancer	2.53e-05	0.000206	CcSEcCtD
Irbesartan—Vomiting—Capecitabine—kidney cancer	2.52e-05	0.000205	CcSEcCtD
Irbesartan—Shock—Doxorubicin—kidney cancer	2.51e-05	0.000204	CcSEcCtD
Irbesartan—Nervous system disorder—Doxorubicin—kidney cancer	2.5e-05	0.000204	CcSEcCtD
Irbesartan—Thrombocytopenia—Doxorubicin—kidney cancer	2.5e-05	0.000203	CcSEcCtD
Irbesartan—Rash—Capecitabine—kidney cancer	2.5e-05	0.000203	CcSEcCtD
Irbesartan—Dermatitis—Capecitabine—kidney cancer	2.49e-05	0.000203	CcSEcCtD
Irbesartan—Tachycardia—Doxorubicin—kidney cancer	2.49e-05	0.000203	CcSEcCtD
Irbesartan—Headache—Capecitabine—kidney cancer	2.48e-05	0.000202	CcSEcCtD
Irbesartan—Skin disorder—Doxorubicin—kidney cancer	2.48e-05	0.000202	CcSEcCtD
Irbesartan—Hyperhidrosis—Doxorubicin—kidney cancer	2.47e-05	0.000201	CcSEcCtD
Irbesartan—Anorexia—Doxorubicin—kidney cancer	2.43e-05	0.000198	CcSEcCtD
Irbesartan—Hypotension—Doxorubicin—kidney cancer	2.38e-05	0.000194	CcSEcCtD
Irbesartan—Nausea—Capecitabine—kidney cancer	2.35e-05	0.000191	CcSEcCtD
Irbesartan—Musculoskeletal discomfort—Doxorubicin—kidney cancer	2.32e-05	0.000189	CcSEcCtD
Irbesartan—Paraesthesia—Doxorubicin—kidney cancer	2.29e-05	0.000186	CcSEcCtD
Irbesartan—Dyspnoea—Doxorubicin—kidney cancer	2.27e-05	0.000185	CcSEcCtD
Irbesartan—Somnolence—Doxorubicin—kidney cancer	2.27e-05	0.000184	CcSEcCtD
Irbesartan—Dyspepsia—Doxorubicin—kidney cancer	2.25e-05	0.000183	CcSEcCtD
Irbesartan—Decreased appetite—Doxorubicin—kidney cancer	2.22e-05	0.00018	CcSEcCtD
Irbesartan—Gastrointestinal disorder—Doxorubicin—kidney cancer	2.2e-05	0.000179	CcSEcCtD
Irbesartan—Fatigue—Doxorubicin—kidney cancer	2.2e-05	0.000179	CcSEcCtD
Irbesartan—Pain—Doxorubicin—kidney cancer	2.18e-05	0.000177	CcSEcCtD
Irbesartan—Constipation—Doxorubicin—kidney cancer	2.18e-05	0.000177	CcSEcCtD
Irbesartan—Feeling abnormal—Doxorubicin—kidney cancer	2.1e-05	0.000171	CcSEcCtD
Irbesartan—Gastrointestinal pain—Doxorubicin—kidney cancer	2.09e-05	0.00017	CcSEcCtD
Irbesartan—Urticaria—Doxorubicin—kidney cancer	2.03e-05	0.000165	CcSEcCtD
Irbesartan—Abdominal pain—Doxorubicin—kidney cancer	2.02e-05	0.000164	CcSEcCtD
Irbesartan—Body temperature increased—Doxorubicin—kidney cancer	2.02e-05	0.000164	CcSEcCtD
Irbesartan—Hypersensitivity—Doxorubicin—kidney cancer	1.88e-05	0.000153	CcSEcCtD
Irbesartan—Asthenia—Doxorubicin—kidney cancer	1.83e-05	0.000149	CcSEcCtD
Irbesartan—Pruritus—Doxorubicin—kidney cancer	1.81e-05	0.000147	CcSEcCtD
Irbesartan—Diarrhoea—Doxorubicin—kidney cancer	1.75e-05	0.000142	CcSEcCtD
Irbesartan—Dizziness—Doxorubicin—kidney cancer	1.69e-05	0.000137	CcSEcCtD
Irbesartan—Vomiting—Doxorubicin—kidney cancer	1.62e-05	0.000132	CcSEcCtD
Irbesartan—Rash—Doxorubicin—kidney cancer	1.61e-05	0.000131	CcSEcCtD
Irbesartan—Dermatitis—Doxorubicin—kidney cancer	1.61e-05	0.000131	CcSEcCtD
Irbesartan—Headache—Doxorubicin—kidney cancer	1.6e-05	0.00013	CcSEcCtD
Irbesartan—Nausea—Doxorubicin—kidney cancer	1.52e-05	0.000123	CcSEcCtD
Irbesartan—EDNRA—Signaling by GPCR—MAPK1—kidney cancer	7e-06	8.85e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism of lipids and lipoproteins—BCHE—kidney cancer	6.99e-06	8.84e-05	CbGpPWpGaD
Irbesartan—JUN—Immune System—KIT—kidney cancer	6.97e-06	8.81e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism of lipids and lipoproteins—CYP1A1—kidney cancer	6.96e-06	8.81e-05	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—BCHE—kidney cancer	6.93e-06	8.76e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—PGK1—kidney cancer	6.88e-06	8.7e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—SLC5A3—kidney cancer	6.88e-06	8.7e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—CCBL1—kidney cancer	6.84e-06	8.66e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—HIF1A—kidney cancer	6.84e-06	8.65e-05	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—SLC5A5—kidney cancer	6.84e-06	8.65e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—TSC2—kidney cancer	6.83e-06	8.63e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—PGK1—kidney cancer	6.82e-06	8.62e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—SLC5A3—kidney cancer	6.82e-06	8.62e-05	CbGpPWpGaD
Irbesartan—JUN—Innate Immune System—MAPK3—kidney cancer	6.77e-06	8.56e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—LDHB—kidney cancer	6.75e-06	8.53e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—GPC3—kidney cancer	6.72e-06	8.5e-05	CbGpPWpGaD
Irbesartan—EDNRA—GPCR downstream signaling—PIK3CA—kidney cancer	6.69e-06	8.46e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—LDHB—kidney cancer	6.69e-06	8.46e-05	CbGpPWpGaD
Irbesartan—EDNRA—Signaling by GPCR—KRAS—kidney cancer	6.61e-06	8.36e-05	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—SLC2A1—kidney cancer	6.61e-06	8.36e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—KDR—kidney cancer	6.55e-06	8.28e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—CA2—kidney cancer	6.54e-06	8.27e-05	CbGpPWpGaD
Irbesartan—JUN—Innate Immune System—MAPK1—kidney cancer	6.44e-06	8.14e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—IGF2—kidney cancer	6.42e-06	8.12e-05	CbGpPWpGaD
Irbesartan—JUN—Immune System—CDH1—kidney cancer	6.41e-06	8.11e-05	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism of lipids and lipoproteins—PTGS2—kidney cancer	6.41e-06	8.11e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—CDKN2B—kidney cancer	6.4e-06	8.09e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—ALAD—kidney cancer	6.37e-06	8.06e-05	CbGpPWpGaD
Irbesartan—UGT1A3—Metabolism—POMC—kidney cancer	6.36e-06	8.04e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—ST3GAL2—kidney cancer	6.22e-06	7.86e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—IGF1R—kidney cancer	6.21e-06	7.85e-05	CbGpPWpGaD
Irbesartan—JUN—Innate Immune System—KRAS—kidney cancer	6.08e-06	7.69e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—ALDH1A1—kidney cancer	6.08e-06	7.69e-05	CbGpPWpGaD
Irbesartan—EDNRA—Signaling by GPCR—PIK3CA—kidney cancer	6.08e-06	7.68e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—CRABP1—kidney cancer	6.06e-06	7.66e-05	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—RAF1—kidney cancer	6.03e-06	7.63e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—APC—kidney cancer	6.03e-06	7.62e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—KIT—kidney cancer	6.03e-06	7.62e-05	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—RELA—kidney cancer	6e-06	7.59e-05	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—ERBB2—kidney cancer	5.97e-06	7.54e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—GLIPR1—kidney cancer	5.93e-06	7.5e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—PPAT—kidney cancer	5.93e-06	7.5e-05	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—MTOR—kidney cancer	5.89e-06	7.45e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—CA9—kidney cancer	5.85e-06	7.4e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—PGK1—kidney cancer	5.83e-06	7.37e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—SLC5A3—kidney cancer	5.83e-06	7.37e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—CA9—kidney cancer	5.8e-06	7.33e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling by GPCR—MAPK3—kidney cancer	5.77e-06	7.3e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—POMC—kidney cancer	5.74e-06	7.26e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—LDHB—kidney cancer	5.72e-06	7.23e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism of lipids and lipoproteins—CYP1A1—kidney cancer	5.67e-06	7.17e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—BRAF—kidney cancer	5.67e-06	7.17e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—ITPR2—kidney cancer	5.63e-06	7.12e-05	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism of lipids and lipoproteins—PTEN—kidney cancer	5.59e-06	7.07e-05	CbGpPWpGaD
Irbesartan—JUN—Innate Immune System—PIK3CA—kidney cancer	5.59e-06	7.07e-05	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—CDKN1B—kidney cancer	5.53e-06	6.99e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—FH—kidney cancer	5.52e-06	6.98e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—APRT—kidney cancer	5.52e-06	6.98e-05	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—GSTP1—kidney cancer	5.51e-06	6.97e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling by GPCR—MAPK1—kidney cancer	5.49e-06	6.95e-05	CbGpPWpGaD
Irbesartan—JUN—Immune System—RAF1—kidney cancer	5.47e-06	6.91e-05	CbGpPWpGaD
Irbesartan—JUN—Immune System—RELA—kidney cancer	5.44e-06	6.88e-05	CbGpPWpGaD
Irbesartan—JUN—Immune System—ERBB2—kidney cancer	5.41e-06	6.84e-05	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—IL2—kidney cancer	5.41e-06	6.84e-05	CbGpPWpGaD
Irbesartan—JUN—Immune System—MTOR—kidney cancer	5.34e-06	6.75e-05	CbGpPWpGaD
Irbesartan—JUN—Immune System—CD4—kidney cancer	5.33e-06	6.74e-05	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—CCND1—kidney cancer	5.27e-06	6.67e-05	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—JUN—kidney cancer	5.26e-06	6.65e-05	CbGpPWpGaD
Irbesartan—AGTR1—GPCR downstream signaling—PIK3CA—kidney cancer	5.25e-06	6.64e-05	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—CTNNB1—kidney cancer	5.22e-06	6.6e-05	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—ABCB1—kidney cancer	5.22e-06	6.6e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism of lipids and lipoproteins—POMC—kidney cancer	5.19e-06	6.57e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling by GPCR—KRAS—kidney cancer	5.19e-06	6.56e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—GPC3—kidney cancer	5.19e-06	6.56e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—ACHE—kidney cancer	5.14e-06	6.49e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—GSTT1—kidney cancer	5.14e-06	6.49e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—HIF1A—kidney cancer	5.11e-06	6.47e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—TSC2—kidney cancer	5.1e-06	6.45e-05	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—PTEN—kidney cancer	5.09e-06	6.43e-05	CbGpPWpGaD
Irbesartan—UGT1A3—Metabolism—PTGS2—kidney cancer	5.07e-06	6.41e-05	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—GSTM1—kidney cancer	5.06e-06	6.4e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—CA2—kidney cancer	5.05e-06	6.38e-05	CbGpPWpGaD
Irbesartan—JUN—Immune System—CDKN1B—kidney cancer	5.01e-06	6.34e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—CRABP1—kidney cancer	4.97e-06	6.29e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—CA9—kidney cancer	4.96e-06	6.27e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—CRABP1—kidney cancer	4.93e-06	6.23e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—ALAD—kidney cancer	4.92e-06	6.22e-05	CbGpPWpGaD
Irbesartan—JUN—Immune System—IL2—kidney cancer	4.9e-06	6.2e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—KDR—kidney cancer	4.89e-06	6.18e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—SCARB1—kidney cancer	4.86e-06	6.15e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism of lipids and lipoproteins—CYP1A1—kidney cancer	4.84e-06	6.12e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—PTGS1—kidney cancer	4.81e-06	6.09e-05	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—CYP1A1—kidney cancer	4.8e-06	6.07e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—ST3GAL2—kidney cancer	4.8e-06	6.07e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling by GPCR—PIK3CA—kidney cancer	4.77e-06	6.03e-05	CbGpPWpGaD
Irbesartan—JUN—Immune System—CTNNB1—kidney cancer	4.73e-06	5.99e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—RAF1—kidney cancer	4.73e-06	5.98e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—PSMD7—kidney cancer	4.72e-06	5.97e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—RELA—kidney cancer	4.71e-06	5.96e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—ALDH1A1—kidney cancer	4.69e-06	5.93e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—ERBB2—kidney cancer	4.68e-06	5.92e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—ITPR2—kidney cancer	4.62e-06	5.85e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—MTOR—kidney cancer	4.62e-06	5.84e-05	CbGpPWpGaD
Irbesartan—JUN—Immune System—PTEN—kidney cancer	4.61e-06	5.83e-05	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—VEGFA—kidney cancer	4.6e-06	5.81e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—ITPR2—kidney cancer	4.58e-06	5.8e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—KIT—kidney cancer	4.5e-06	5.7e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—APC—kidney cancer	4.5e-06	5.7e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—SLC5A3—kidney cancer	4.5e-06	5.69e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—PGK1—kidney cancer	4.5e-06	5.69e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—BCHE—kidney cancer	4.47e-06	5.66e-05	CbGpPWpGaD
Irbesartan—UGT1A3—Metabolism—PTEN—kidney cancer	4.42e-06	5.59e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—SLC5A5—kidney cancer	4.42e-06	5.59e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—LDHB—kidney cancer	4.41e-06	5.58e-05	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—MAPK3—kidney cancer	4.35e-06	5.5e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—CDKN1B—kidney cancer	4.34e-06	5.48e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—POMC—kidney cancer	4.29e-06	5.42e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—SLC2A1—kidney cancer	4.27e-06	5.4e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—IL2—kidney cancer	4.24e-06	5.37e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—BRAF—kidney cancer	4.23e-06	5.35e-05	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—MYC—kidney cancer	4.23e-06	5.35e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism of lipids and lipoproteins—POMC—kidney cancer	4.23e-06	5.34e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—ACHE—kidney cancer	4.22e-06	5.33e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—GSTT1—kidney cancer	4.22e-06	5.33e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—CRABP1—kidney cancer	4.21e-06	5.33e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—GSTT1—kidney cancer	4.18e-06	5.29e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—ACHE—kidney cancer	4.18e-06	5.29e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—kidney cancer	4.14e-06	5.24e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—CCND1—kidney cancer	4.14e-06	5.23e-05	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—MAPK1—kidney cancer	4.14e-06	5.23e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—JUN—kidney cancer	4.13e-06	5.22e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—CTNNB1—kidney cancer	4.1e-06	5.18e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—PTEN—kidney cancer	3.99e-06	5.05e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—SCARB1—kidney cancer	3.99e-06	5.05e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—SCARB1—kidney cancer	3.96e-06	5e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—PTGS1—kidney cancer	3.95e-06	5e-05	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism of lipids and lipoproteins—PIK3CA—kidney cancer	3.94e-06	4.99e-05	CbGpPWpGaD
Irbesartan—JUN—Immune System—MAPK3—kidney cancer	3.94e-06	4.98e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—ITPR2—kidney cancer	3.92e-06	4.95e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—PTGS1—kidney cancer	3.92e-06	4.95e-05	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—KRAS—kidney cancer	3.91e-06	4.94e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—PSMD7—kidney cancer	3.87e-06	4.9e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—PSMD7—kidney cancer	3.84e-06	4.86e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—CA9—kidney cancer	3.82e-06	4.84e-05	CbGpPWpGaD
Irbesartan—JUN—Immune System—MAPK1—kidney cancer	3.75e-06	4.74e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—BCHE—kidney cancer	3.67e-06	4.64e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—BCHE—kidney cancer	3.64e-06	4.6e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—SLC5A5—kidney cancer	3.63e-06	4.59e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism of lipids and lipoproteins—PTEN—kidney cancer	3.61e-06	4.57e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism of lipids and lipoproteins—POMC—kidney cancer	3.61e-06	4.57e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—VEGFA—kidney cancer	3.61e-06	4.56e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—SLC5A5—kidney cancer	3.6e-06	4.55e-05	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—PIK3CA—kidney cancer	3.59e-06	4.54e-05	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—POMC—kidney cancer	3.58e-06	4.53e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—ACHE—kidney cancer	3.57e-06	4.52e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—GSTT1—kidney cancer	3.57e-06	4.52e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—GSTP1—kidney cancer	3.56e-06	4.5e-05	CbGpPWpGaD
Irbesartan—JUN—Immune System—KRAS—kidney cancer	3.54e-06	4.48e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—RAF1—kidney cancer	3.54e-06	4.47e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—RELA—kidney cancer	3.52e-06	4.45e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—SLC2A1—kidney cancer	3.5e-06	4.43e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—ERBB2—kidney cancer	3.5e-06	4.42e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—SLC2A1—kidney cancer	3.47e-06	4.39e-05	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—TP53—kidney cancer	3.47e-06	4.39e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—MTOR—kidney cancer	3.45e-06	4.36e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—MAPK3—kidney cancer	3.41e-06	4.31e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—SCARB1—kidney cancer	3.38e-06	4.28e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—kidney cancer	3.37e-06	4.26e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—ABCB1—kidney cancer	3.37e-06	4.26e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—PTGS1—kidney cancer	3.35e-06	4.23e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—MYC—kidney cancer	3.32e-06	4.2e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—PSMD7—kidney cancer	3.28e-06	4.15e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—GSTM1—kidney cancer	3.27e-06	4.14e-05	CbGpPWpGaD
Irbesartan—JUN—Immune System—PIK3CA—kidney cancer	3.25e-06	4.12e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—CRABP1—kidney cancer	3.25e-06	4.11e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—MAPK1—kidney cancer	3.25e-06	4.1e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—CDKN1B—kidney cancer	3.24e-06	4.1e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—IL2—kidney cancer	3.17e-06	4.01e-05	CbGpPWpGaD
Irbesartan—UGT1A3—Metabolism—PIK3CA—kidney cancer	3.12e-06	3.94e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—BCHE—kidney cancer	3.11e-06	3.93e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—CYP1A1—kidney cancer	3.1e-06	3.92e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—CCND1—kidney cancer	3.09e-06	3.91e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—SLC5A5—kidney cancer	3.07e-06	3.89e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—KRAS—kidney cancer	3.07e-06	3.88e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—CTNNB1—kidney cancer	3.06e-06	3.87e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—ITPR2—kidney cancer	3.02e-06	3.82e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—PTEN—kidney cancer	2.98e-06	3.77e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—SLC2A1—kidney cancer	2.97e-06	3.75e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—kidney cancer	2.94e-06	3.72e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—GSTP1—kidney cancer	2.92e-06	3.7e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—GSTP1—kidney cancer	2.9e-06	3.66e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—kidney cancer	2.88e-06	3.64e-05	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—PTGS2—kidney cancer	2.86e-06	3.61e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—PIK3CA—kidney cancer	2.82e-06	3.56e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—ABCB1—kidney cancer	2.77e-06	3.5e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—GSTT1—kidney cancer	2.76e-06	3.49e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—ACHE—kidney cancer	2.76e-06	3.49e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—ABCB1—kidney cancer	2.74e-06	3.47e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—TP53—kidney cancer	2.72e-06	3.45e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—VEGFA—kidney cancer	2.69e-06	3.41e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—GSTM1—kidney cancer	2.69e-06	3.4e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—GSTM1—kidney cancer	2.66e-06	3.37e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—SCARB1—kidney cancer	2.61e-06	3.3e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—PTGS1—kidney cancer	2.58e-06	3.27e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—MAPK3—kidney cancer	2.55e-06	3.22e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—kidney cancer	2.55e-06	3.22e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—CYP1A1—kidney cancer	2.55e-06	3.22e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—PSMD7—kidney cancer	2.53e-06	3.2e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—CYP1A1—kidney cancer	2.52e-06	3.19e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—kidney cancer	2.51e-06	3.18e-05	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—PTEN—kidney cancer	2.49e-06	3.15e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—MYC—kidney cancer	2.48e-06	3.13e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—GSTP1—kidney cancer	2.48e-06	3.13e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—MAPK1—kidney cancer	2.42e-06	3.07e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—BCHE—kidney cancer	2.4e-06	3.04e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—SLC5A5—kidney cancer	2.37e-06	3e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—ABCB1—kidney cancer	2.34e-06	2.96e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—POMC—kidney cancer	2.31e-06	2.92e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—SLC2A1—kidney cancer	2.29e-06	2.9e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—KRAS—kidney cancer	2.29e-06	2.9e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—GSTM1—kidney cancer	2.28e-06	2.88e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—CYP1A1—kidney cancer	2.16e-06	2.73e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—PIK3CA—kidney cancer	2.1e-06	2.66e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—kidney cancer	2.07e-06	2.62e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—TP53—kidney cancer	2.04e-06	2.57e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—GSTP1—kidney cancer	1.91e-06	2.42e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—POMC—kidney cancer	1.9e-06	2.4e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—POMC—kidney cancer	1.88e-06	2.38e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—PTGS2—kidney cancer	1.84e-06	2.33e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—ABCB1—kidney cancer	1.81e-06	2.29e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—kidney cancer	1.77e-06	2.24e-05	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—PIK3CA—kidney cancer	1.76e-06	2.22e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—GSTM1—kidney cancer	1.76e-06	2.22e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—CYP1A1—kidney cancer	1.66e-06	2.1e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—PTEN—kidney cancer	1.61e-06	2.03e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—POMC—kidney cancer	1.61e-06	2.03e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—PTGS2—kidney cancer	1.51e-06	1.91e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—PTGS2—kidney cancer	1.5e-06	1.9e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—PTEN—kidney cancer	1.32e-06	1.67e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—PTEN—kidney cancer	1.31e-06	1.66e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—PTGS2—kidney cancer	1.28e-06	1.62e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—POMC—kidney cancer	1.24e-06	1.57e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—PIK3CA—kidney cancer	1.13e-06	1.43e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—PTEN—kidney cancer	1.12e-06	1.41e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—PTGS2—kidney cancer	9.9e-07	1.25e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—PIK3CA—kidney cancer	9.32e-07	1.18e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—PIK3CA—kidney cancer	9.23e-07	1.17e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—PTEN—kidney cancer	8.63e-07	1.09e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—PIK3CA—kidney cancer	7.89e-07	9.98e-06	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—PIK3CA—kidney cancer	6.09e-07	7.7e-06	CbGpPWpGaD
